Engineers Gate Manager LP bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 69,691 shares of the medical equipment provider’s stock, valued at approximately $3,855,000. Engineers Gate Manager LP owned approximately 0.10% of Lantheus at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Graham Capital Management L.P. bought a new position in shares of Lantheus in the first quarter worth approximately $1,299,000. Hood River Capital Management LLC lifted its position in Lantheus by 29.8% during the first quarter. Hood River Capital Management LLC now owns 1,079,197 shares of the medical equipment provider’s stock valued at $59,690,000 after buying an additional 247,868 shares during the period. Maven Securities LTD purchased a new position in shares of Lantheus in the 1st quarter worth about $2,023,000. Invesco Ltd. raised its position in shares of Lantheus by 1.3% in the 1st quarter. Invesco Ltd. now owns 522,633 shares of the medical equipment provider’s stock worth $28,908,000 after purchasing an additional 6,706 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of Lantheus by 63.7% in the 1st quarter. Hsbc Holdings PLC now owns 19,875 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 7,736 shares during the last quarter. 98.14% of the stock is owned by hedge funds and other institutional investors.
Lantheus Stock Performance
NASDAQ:LNTH opened at $85.05 on Friday. The stock’s fifty day moving average is $75.96 and its 200 day moving average is $65.26. Lantheus Holdings, Inc. has a fifty-two week low of $22.20 and a fifty-two week high of $86.85. The firm has a market capitalization of $5.85 billion, a PE ratio of 197.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.69 and a current ratio of 1.85.
Insider Buying and Selling at Lantheus
In other Lantheus news, CAO Andrea Sabens sold 1,093 shares of the company’s stock in a transaction on Monday, July 18th. The stock was sold at an average price of $71.47, for a total value of $78,116.71. Following the transaction, the chief accounting officer now owns 63,162 shares of the company’s stock, valued at approximately $4,514,188.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, CFO Robert J. Jr. Marshall sold 5,000 shares of the stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $82.82, for a total value of $414,100.00. Following the completion of the sale, the chief financial officer now directly owns 130,893 shares in the company, valued at $10,840,558.26. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Andrea Sabens sold 1,093 shares of the stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $71.47, for a total value of $78,116.71. Following the completion of the sale, the chief accounting officer now owns 63,162 shares of the company’s stock, valued at $4,514,188.14. The disclosure for this sale can be found here. Insiders have sold 8,751 shares of company stock valued at $700,218 in the last quarter. 1.60% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on LNTH. B. Riley reissued a “buy” rating on shares of Lantheus in a research report on Thursday, August 25th. SVB Leerink boosted their price objective on Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Friday, August 5th.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.